Agenus

  • Scientist, Immune Receptor Discovery - AgenTus Therapeutics (Cambridge UK)

    Job Locations UK-Cambridge
    Posted Date 2 weeks ago(4/4/2018 6:48 AM)
    ID
    2018-1360
    Category
    Research
  • Overview

    Due to further growth of our company we have a number of new openings, including a Research Scientist to join our Immune Receptor Discovery team

     

    If you are an enthusiastic and innovative team-player, who has a scientific background as below, and are looking to join a highly motivated team in a dynamic international environment, we would love to receive your application and get to know you further.

     

    Responsibilities

    • Develop and implement protocols for gene engineering in primary T-cells (eg. TCR/ CAR introduction by using transposons/ viruses etc). 
    • Perform TCR/ CAR characterization of the edited T cells through e.g. cell killing and activation assays. 
    • Contribute to the mammalian display screening platform.
    • Ensure timely delivery of data analysis packages and accurate recording of the sample-to-data process.
    • Responsible for high quality of documentation, laboratory notebooks and protocol.
    • The successful candidate will also work closely with our Molecular Biology and Bioinformatics teams, as well as with the Protein Sciences and international immunobiology and T-cell sciences teams. 

     

    Qualifications

    • PhD in immunology/cell biology with at least 2 years relevant postdoctoral training or equivalent industry experience,
    • or MSc with at least 5 years relevant industry experience. 

     

    Experience

    • Hands-on T cell isolation and expansion skills.
    • Previous experience with gene editing technologies (lentiviruses, transposons etc) preferably in human T-cells.
    • Industry experience an asset.
    • Previous experience with multi-color flow cytometry, T-cell function assays and molecular biology a plus. 

     

    More about AgenTus Therapeutics....

    Agentus Therapeutics is a biopharmaceutical company, and subsidiary of Agenus Inc, focusing on the discovery, development, and commercialization of breakthrough “living drugs” to advance cures for cancer patients. AgenTus employs naturally-derived and engineered receptors, specifically T Cell Receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to supercharge human immune effector cells to seek and destroy cancer. AgenTus will also aim to advance adoptive cell therapy formats which would enable off-the-shelf living drugs.

     

     

     

     

    Options

    Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
    Share on your newsfeed